Terms: = Breast cancer AND MPL, TPOR, P40238, 4352, ENSG00000117400, CD110, MPLV, C-MPL, RP1-92O14_1 AND Clinical Outcome
1422 results:
1. Caveolin-1 gene expression provides additional prognostic information combined with PAM50 risk of recurrence (ROR) score in breast cancer.
Godina C; Belting M; Vallon-Christersson J; Isaksson K; Bosch A; Jernström H
Sci Rep; 2024 Mar; 14(1):6675. PubMed ID: 38509243
[TBL] [Abstract] [Full Text] [Related]
2. Conditional generative adversarial network driven radiomic prediction of mutation status based on magnetic resonance imaging of breast cancer.
Huang ZH; Chen L; Sun Y; Liu Q; Hu P
J Transl Med; 2024 Mar; 22(1):226. PubMed ID: 38429796
[TBL] [Abstract] [Full Text] [Related]
3. NAT10-mediated mRNA N4-acetylcytidine modification of MDR1 and BCRP promotes breast cancer progression.
Zhao CC; Sun X; Chen J; Geng BD
Thorac Cancer; 2024 Apr; 15(10):820-829. PubMed ID: 38409918
[TBL] [Abstract] [Full Text] [Related]
4. PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer.
Wang L; Guo W; Guo Z; Yu J; Tan J; Simons DL; Hu K; Liu X; Zhou Q; Zheng Y; Colt EA; Yim J; Waisman J; Lee PP
Cell Rep Med; 2024 Feb; 5(2):101420. PubMed ID: 38382468
[TBL] [Abstract] [Full Text] [Related]
5. Tumor budding in breast carcinoma: A systematic review and meta-analysis.
Buch A; Khan U; Rathod H; Jain K; Dwivedi A; Rajesh A
J Cancer Res Ther; 2023 Oct; 19(7):1697-1713. PubMed ID: 38376268
[TBL] [Abstract] [Full Text] [Related]
6. Plateletcrit is predictive of clinical outcome and prognosis for early-stage breast cancer: A retrospective cohort study based on propensity score matching.
Zhao X; Yang Y; Pan Z; Lv W; Rao X; Wang X; Yu X
Cancer Med; 2024 Jan; 13(2):e6944. PubMed ID: 38348939
[TBL] [Abstract] [Full Text] [Related]
7. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
8. Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patients.
Saldajeno DP; Kawaoka S; Masuda N; Tanaka S; Bando H; Nishimura T; Kadoya T; Yamanaka T; Imoto S; Velaga RM; Tamura N; Aruga T; Ikeda K; Fukui Y; Maeshima Y; Takada M; Suzuki E; Ueno T; Ogawa S; Haga H; Ohno S; Morita S; Kawaguchi K; Toi M
Br J Cancer; 2024 Apr; 130(6):1023-1035. PubMed ID: 38238427
[TBL] [Abstract] [Full Text] [Related]
9. LncRNA SOX9-AS1 triggers a transcriptional program involved in lipid metabolic reprogramming, cell migration and invasion in triple-negative breast cancer.
Cisneros-Villanueva M; Fonseca-Montaño MA; Ríos-Romero M; López-Camarillo C; Jiménez-Morales S; Langley E; Rosette-Rueda AS; Cedro-Tanda A; Hernández-Sotelo D; Hidalgo-Miranda A
Sci Rep; 2024 Jan; 14(1):1483. PubMed ID: 38233470
[TBL] [Abstract] [Full Text] [Related]
10. Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes.
Dimitrakopoulos FI; Goussia A; Koliou GA; Dadouli K; Batistatou A; Kourea HP; Bobos M; Arapantoni-Dadioti P; Tzaida O; Koletsa T; Chrisafi S; Sotiropoulou M; Papoudou-Bai A; Nicolaou I; Charchanti A; Mauri D; Aravantinos G; Binas I; Res E; Psyrri A; Pectasides D; Bafaloukos D; Koumarianou A; Bompolaki I; Rigakos G; Karanikiotis C; Koutras A; Zagouri F; Gogas H; Fountzilas G
Breast; 2024 Feb; 73():103668. PubMed ID: 38176305
[TBL] [Abstract] [Full Text] [Related]
11. clinical characteristics and prognosis of primary small cell carcinoma of the breast: a propensity score-matched, population-based study.
Yin L; Yin AH; Pu CC
BMJ Open; 2023 Dec; 13(12):e073841. PubMed ID: 38097248
[TBL] [Abstract] [Full Text] [Related]
12. Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative breast cancer.
Coakley M; Villacampa G; Sritharan P; Swift C; Dunne K; Kilburn L; Goddard K; Pipinikas C; Rojas P; Emmett W; Hall P; Harper-Wynne C; Hickish T; Macpherson I; Okines A; Wardley A; Wheatley D; Waters S; Palmieri C; Winter M; Cutts RJ; Garcia-Murillas I; Bliss J; Turner NC
Clin Cancer Res; 2024 Feb; 30(4):895-903. PubMed ID: 38078899
[TBL] [Abstract] [Full Text] [Related]
13. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
14. A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic breast cancer.
Cescon DW; Hilton J; Morales Murilo S; Layman RM; Pluard T; Yeo B; Park IH; Provencher L; Kim SB; Im YH; Wyce A; Krishnatry AS; Hicks K; Zhang Q; Barbash O; Khaled A; Horner T; Dhar A; Oliveira M; Sparano JA
Clin Cancer Res; 2024 Jan; 30(2):334-343. PubMed ID: 37992310
[TBL] [Abstract] [Full Text] [Related]
15. Vascular endothelial growth factor (VEGF) -A, -C and VE-cadherin as potential biomarkers in early breast cancer patients.
Milovanović J; Vujasinović T; Todorović-Raković N; Greenman J; Hranisavljević J; Radulovic M
Pathol Res Pract; 2023 Dec; 252():154923. PubMed ID: 37948997
[TBL] [Abstract] [Full Text] [Related]
16. Adapting and implementing breast cancer follow-up in primary care: protocol for a mixed methods hybrid type 1 effectiveness-implementation cluster randomized study.
Fadem SJ; Crabtree BF; O'Malley DM; Mikesell L; Ferrante JM; Toppmeyer DL; Ohman-Strickland PA; Hemler JR; Howard J; Bator A; April-Sanders A; Kurtzman R; Hudson SV
BMC Prim Care; 2023 Nov; 24(1):235. PubMed ID: 37946132
[TBL] [Abstract] [Full Text] [Related]
17. PTPN1 is a prognostic biomarker related to cancer immunity and drug sensitivity: from pan-cancer analysis to validation in breast cancer.
Zhao R; Chen S; Cui W; Xie C; Zhang A; Yang L; Dong H
Front Immunol; 2023; 14():1232047. PubMed ID: 37936713
[TBL] [Abstract] [Full Text] [Related]
18. clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan.
Baba T; Kusumoto M; Kato T; Kurihara Y; Sasaki S; Oikado K; Saito Y; Endo M; Fujiwara Y; Kenmotsu H; Sata M; Takano T; Kato K; Hirata K; Katagiri T; Saito H; Kuwano K
Int J Clin Oncol; 2023 Dec; 28(12):1585-1596. PubMed ID: 37787866
[TBL] [Abstract] [Full Text] [Related]
19. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas.
Uğurluoğlu C; Yormaz S
Pathol Res Pract; 2023 Oct; 250():154828. PubMed ID: 37778126
[TBL] [Abstract] [Full Text] [Related]
20. GK-1 effectively reduces angiogenesis and prevents T cell exhaustion in a breast cancer murine experimental model.
Hernández-Aceves JA; Cervantes-Torres J; Torres-García D; Zuñiga-Flores FJ; Patiño-Chávez OJ; Peña Agudelo JA; Aguayo-Flores JE; Garfias Y; Montero-León L; Romero-Romero L; Pérez-Torres A; Fragoso G; Sciutto E
Cancer Immunol Immunother; 2023 Nov; 72(11):3825-3838. PubMed ID: 37736849
[TBL] [Abstract] [Full Text] [Related]
[Next]
